Table 1. Clinical characteristics of the study population.
| Characteristic | Mild (n=196) | Moderate (n=195) | Severe (n=196) | P |
|---|---|---|---|---|
| Age (years) | 64.4±12.2 | 65.5±12.9 | 64.9±13.9 | 0.72 |
| Gender (female) | 116 | 124 | 101 | 0.05 |
| Ethnicity (European) | 174 | 182 | 167 | 0.03 |
| Diagnosis | 0.77 | |||
| POAG | 88 | 91 | 96 | |
| NTG | 33 | 23 | 25 | |
| XFG | 29 | 27 | 28 | |
| Other | 46 | 54 | 47 | |
| Mean Baseline MD (dB) | −2.4±1.2 | −6.1±1.2 | −12.9±4.3 | <0.01a |
| Mean follow-up IOP (mm Hg) | 16.0±3.2 | 15.5±3.1 | 14.2±2.6 | <0.01b |
| Peak IOP (mm Hg) | 20.5±4.6 | 20.3±4.9 | 18.8±3.7 | <0.01b |
| CCT (μm) | 544.9±37.1 | 542.0±36.8 | 535.8±37.5 | 0.04c |
| Follow-up time (years) | 11.2±3.3 | 11.1±3.1 | 10.9±2.7 | 0.23 |
| Number of VF tests | 6.5±1.8 | 6.4±1.6 | 6.2±1.8 | 0.56 |
| Global rate of VF change (dB per year) | −0.5±0.9 | −0.4±0.6 | −0.3±0.5 | 0.03c |
| Number of progressing eyes | 58 | 61 | 51 | 0.50 |
a
Significant difference among the three subgroups.
b
Significant differences between the mild and moderate subgroups and the severe subgroup.
c
Significant difference between the mild and severe subgroups.